

GLAXOSMITHKLINE PLC

Form 6-K

January 13, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 13 January 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☐ Form 40-F ☒

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes ☐ No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Sir Andrew Witty
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')				
	ISIN: GB0009252882				
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.				
c) Price(s) and volume(s)	<table border="0"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">£15.7242</td> <td style="text-align: right;">7299</td> </tr> </table>	Price(s)	Volume(s)	£15.7242	7299
Price(s)	Volume(s)				
£15.7242	7299				
	n/a (single transaction)				
d) Aggregated information Aggregated volume Price					
e) Date of the transaction	2017-01-12				
f) Place of the transaction	London Stock Exchange (XLON)				

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Lady C Witty
 - b) Position/status PCA of Sir Andrew Witty (Chief Executive Officer)
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	Ordinary shares of 25 pence each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.
	Price(s) Volume(s)
c) Price(s) and volume(s)	£15.7242 2078
	n/a (single transaction)
d) Aggregated information	
Aggregated volume Price	
e) Date of the transaction	2017-01-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr J P Witty
b) Position/status	PCA of Sir Andrew Witty (Chief Executive Officer)
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	Ordinary shares of 25 pence each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of ordinary shares following the re-investment of dividends paid to shareholders on 12 January 2017.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7242	60

n/a (single transaction)

d) Aggregated information
Aggregated volume Price

e) Date of the transaction	2017-01-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms S Witty
b) Position/status	PCA of Sir Andrew Witty (Chief Executive Officer)

c) Initial notification/ amendment	Initial notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence
each ('Ordinary Shares')

a) Description of the financial instrument	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.
------------------------------	--

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7242	63

n/a (single transaction)

d) Aggregated information
Aggregated volume Price

e) Date of the transaction	2017-01-12
f) Place of the transaction	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr I W Whyte
 - b) Position/status PCA of Mrs V A Whyte
(Company Secretary)
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	Ordinary shares of 25 pence each ('Ordinary Shares')	
a) Description of the financial instrument	ISIN: GB0009252882	
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.	
	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.7242	500
	n/a (single transaction)	
d) Aggregated information		
Aggregated volume Price		
e) Date of the transaction	2017-01-12	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mrs D Connor
 - b) Position/status PCA of Mr R G Connor
(President, Global Manufacturing & Supply)
 - c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')						
	ISIN: GB0009252882						
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 January 2017.						
c) Price(s) and volume(s)	<table border="0" style="margin-left: 20px;"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">£15.7242</td> <td style="text-align: right;">237</td> </tr> <tr> <td colspan="2" style="text-align: right;">n/a (single transaction)</td> </tr> </table>	Price(s)	Volume(s)	£15.7242	237	n/a (single transaction)	
Price(s)	Volume(s)						
£15.7242	237						
n/a (single transaction)							
d) Aggregated information	Aggregated volume Price						
e) Date of the transaction	2017-01-12						
f) Place of the transaction	London Stock Exchange (XLON)						

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 13, 2017

By: VICTORIA WHYTE-----

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc